Newsfeeds - Spark Newswire

1 minute read

eFFECTOR Therapeutics Q4 EPS $(0.22) Beats $(0.24) Estimate, Sales $674.00K Beat $660.00K Estimate

Today, 2:11 PM

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is a 150 percent decrease over earnings of $0.44 per share

EFTR

3 minute read

S&P 500 Down 2%; Mobilicom Shares Spike Higher

By Lisa Levin

Today, 2:11 PM

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday. The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The S&P 500 also fell, dropping, 2.05% to 3,995.66.

ALRN

4 minute read

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 2:11 PM

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

AKAN

3 minute read

Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February

By Lisa Levin

Today, 2:11 PM

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 500 points on Tuesday. The Dow traded down 1.61% to 33,280.92 while the NASDAQ fell 2.05% to 11,545.79. The S&P 500 also fell, dropping, 1.65% to 4,011.67.

ALRN

1 minute read

JMP Securities Maintains Market Outperform on eFFECTOR Therapeutics, Lowers Price Target to $1

By Benzinga Newsdesk

Today, 2:11 PM

JMP Securities analyst Reni Benjamin maintains eFFECTOR Therapeutics (NASDAQ:EFTR) with a Market Outperform and lowers the price target from $2 to $1.

EFTR

3 minute read

Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

Today, 2:11 PM

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.

ABVC

1 minute read

eFFECTOR Therapeutics Shares Jump After Clinical Update Of Investigational Cancer Drug

By Vandana Singh

Today, 2:11 PM

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) provided an update on its ongoing clinical development programs for zotatifin, in Phase 2 expansion cohorts for…

EFTR

1 minute read

News

eFFECTOR Therapeutics Provides Clinical Data Update For Zotatifin, General Corporate Update

By Michael Horton

Today, 2:11 PM

Zotatifin program update as of December 15, 2022: In the cohort (n=7) receiving zotatifin, fulvestrant and abemaciclib (ECBF+A), two patients experienced confirmed PRs, and a third patient had stable disease

EFTR